Methods: Source population was pts from 3 MEL cohorts treated with MK-3475 2 mg/kg every 3 wk (Q3W), 10 mg/kg Q3W, or 10 mg/kg Q2W in a phase I trial. Tumor imaging was performed every 12 wk. Response was assessed by irRC and RECIST 1.1 by central review; irRC was used for pt management. Tumor flare and atypical delayed response were identified by using centrally assessed irRC data among pts on MK-3475 for ≥28 wk. Tumor flare was defined as unconfirmed PD at assessment 1 (ie, wk 12) and non-PD at assessment 2. Atypical delayed response was defined as PD at any time point followed by non-PD and then response. Survival data were analyzed in pts who had PD by RECIST but CR/PR/SD by irRC.
Results: Among the 411 pts enrolled across the 3 MEL cohorts, 192 were on MK-3475 for ≥28 wk as of the analysis cut-off of 10/18/2013. Tumor flare was seen in 7 (3.6%) pts. In these pts, best overall response per irRC was CR (n = 1), PR (n = 4), and SD (n = 2). Atypical delayed response was seen in 6 (3.1%) pts. The 51 pts with PD by RECIST but CR/PR/SD by irRC had favorable OS compared with the 145 pts with PD by both criteria (Table).
Conclusions: MEL pts treated with MK-3475 may experience unique patterns of response and should be managed accordingly. Similar to what has been observed with ipilimumab, conventional criteria such as RECIST may underestimate the benefit of MK-3475 in approximately 10% of treated pts. An updated version of response criteria that incorporate new data on PD-1 inhibitors may be appropriate for future consideration. Clinical trial information: NCT01295827.
|Number of pages||1|
|Journal||Journal of Clinical Oncology|
|Issue number||15 Supplementary|
|Publication status||Published - 20 May 2014|
|Event||50th Annual Meeting of the American-Society-of-Clinical-Oncology - Chicago, United States|
Duration: 30 May 2014 → 3 Jun 2014